| AZ | EN | RU

STATISTICS


SIGNIFICANCE OF TISSUE INHIBITOR METALLOPROTEINASE-1 IN THE PATHOGENESIS BREAST CANCER
Gambarova S.C.

DOI: 10.61775/2413-3302.v2i32.01

ABSTRACT
Tissue metalloproteinase inhibitors (MPTIs) play an important role in the pathogenesis of breast cancer (BC). Although recent studies have shown the dual role of MPTIs in the development of this pathology, it has been proven that they inhibit the activity of metalloproteinases prevent invasiveness and tumor recurrence. Conducting extensive research towards studying the antitumor effect of these protease inhibitors, especially MPTI-1, may allow the development of new drugs for the treatment of breast cancer.
Keywords: breast cancer, metalloproteinases, tissue inhibitors of metalloproteinases

REFERENCES
  1. Deryugina E.I. Matrix metalloproteinases and tumor metastasis // Cancer Metastasis Rev., 2006; 25 (1): 9-34.
  2. Deryugina E.I. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions // Biochim. Biophys. Acta., 2010; 1803 (1): 103-120.
  3. Черномаз И.С. Клиническое значение матриксных металлопротеиназ и их тканевых ингибиторов у больных опухолями костей / диссертация кандидата медицинских наук, - Москва - 2020.
  4. Kessenbrock K. Matrix metalloproteinases: regulators of the tumor microenvironment // Cell., 2010; 141(1): 52-67.
  5. Васильевна Ю.К. Клиническая значимость матриксной металлопротеиназы 2 типа и ангиогенных факторов в сыворотке крови и опухоли больных новообразованиями яичников / диссертация кандидата медицинских наук, - Москва - 2011.
  6. Roy D.M. Candidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitors // Breast Cancer., 2014; 6: 81-91.
  7. Герштейн Е.С., Кушлинский Д.Н., Адамян Л.В. и др. Матриксные мeталлопротеиназы и их тканевые ингибиторы в клиническом течении и прогнозе рака яичников // Молекулярная медицина, 2013; 6: 11-20.
  8. Ганусевич И.И. Роль матриксных металлопротеиназ (ММП) при злокачественных новообразованиях. и участие ММП в ангиогенезе, инвазии и метастазировании опухолей // Онкология, 2010; 12 (2): 108-117.
  9. Ярмолинская М.И., Молотков, А.С., Денисова, В.М. Матриксные металлопротеиназы и ингибиторы: классификация, механизм действия // Журнал акушерства и женских болезней, 2012; 61 (1): 113-125.
  10. Матриксные металлопротеиназы, c. 445-449; www. Biochemmack.ru
  11. Мамедов У.Р. Инсулиноподобные факторы роста и маркеры опухолевой прогрессии в диагностике и прогнозе раннего рецидива рака молочной железы // диссертация кандидата медицинских наук, - Москва - 2019.
  12. Chimal-Ramírez G.K., Espinoza-Sánchez N.A., Utrera-Barillas D. et al. MMP1, MMP9, and COX2 expressions in promonocytes are induced by breast cancer cells and correlate with collagen degradation, transformation-like morphological changes in MCF-10A acini, and tumor aggressiveness // Biomed. Res. Int., 2013: 279505.
  13. Kulic A. Dedic Plavetic, Vrbanec J., Sirotkovic-Skerlev M. Low serum MMP-1 in breast cancer: a negative prognostic factor? // Biomarkers., 2012; 17(5): 416-421.
  14. Puzovic V. Brcic I., Ranogajec I. et al. Prognostic values of ETS-1, MMP-2 and MMP-9 expression and co-expression in breast cancer patients // Neoplasma, 2014; 61 (4): 439-446.
  15. Song J., Su H., Zhou Y.Y. et al. Prognostic value of matrix metalloproteinase 9 expression in breast cancer patients: a meta-analysis // Asian Pac. J. Cancer Prev., 2013; 14 (3):1615-1621.
  16. Murphy G., Nagase H. Progress in matrix metalloproteinase research // Mol. Aspects Med., 2008; 29 (5): 290-308.
  17. Chou A., Hsiao C., Shih T. et al. The Contribution of Matrix Metalloproteinase-7 Promoter Genotypes in Breast Cancer in Taiwan // Anticancer Research, 2017; 37(9): 4973-4977.
  18. Григоркевич О.С., Мокров Г.В., Косова Л.Ю. Матриксные металлопротеиназы и их ингибиторы // Фармакокинетика и Фармакодинамика, 2019;(2):3-16
  19. Клишо Е.В., Кондакова И.В., Чойнзонов Е.Л. Матриксные металлопротеиназы в онкогенезе // Сибирский онкологический журнал, 2003; 2: 62-70.
  20. Рогова Л.Н., Шестернина Н.В., Замечник Т.В., Фастова И.А. Матриксные металлопротеиназы, их роль в физиологических и патологических процессах (обзор) // Вестник новых медицинских технологий, 2011; XVIII (2): 86-89.
  21. Würtz S.O., Schrohl A.S., Sørensen N.M. et al. Tissue inhibitor of metalloproteinases-1 in breast cancer // Endocr Relat Cancer, 2005; 12(2):215-27.
  22. Yoshiji H, Gomez D.E., Thorgeirsson U.P. Enhanced RNA expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in human breast cancer // International Journal of Cancer (Pred. Oncol.), 1996; 69: 131-134.
  23. Brummer O., Athar S., Riethdorf L. et al. Matrix-metalloproteinases 1,2 and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridisation study // Virchows Archiv, 1999; 435:566-573.
  24. Nakopoulou L., Panayotopoulou E.G., Giannopoulou I. et al. Stromelysin-3 protein expression in invasive breast cancer: relation to proliferation, cell survival and patients’ outcome // Modern Pathology, 2002;15:1154-1161.
  25. Jones J.L., Glynn P., Walker R.A. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas, Journal of Pathology, 1999; 189: 161-168.
  26. Abdollahi A., Nozarian Z., Nazar E. Association between Expression of Tissue Inhibitors of Metalloproteinases-1, Matrix Metalloproteinase-2, and Matrix Metalloproteinase-9 Genes and Axillary Lymph Nodes Metastasis in Patients with Breast Cancer. Int J Prev Med. 2019;10:127.
  27. Thorsen S.B., Christensen S.L., Würtz S.O. et al. Plasma levels of the MMP-9:TIMP-1 complex as prognostic biomarker in breast cancer: A retrospective study // BMC Cancer., 2013;13:598.
  28. Brun J., Cortez A., Lesieur B. et al. Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer // Oncol Rep., 2012; 27: 1049-1057.
  29. Radisky E.S., Raeeszadeh-Sarmazdeh M., Radisky D.C. Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer // J Cell Biochem., 2017;118(11):3531-3548.
  30. Sonego M., Poletto E., Pivetta E. et al. TIMP-1 is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells // Cells, 2019;9(1):6.
  31. Gong Y., Scott E., Lu R. et al. TIMP-1 promotes accumulation of cancer associated fibroblasts and cancer progression // PLoS One, 2013;8(10):e77366
  32. Winer A., Adams S., Mignatti P. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes // Mol Cancer Ther., 2018; 17(6): 1147-1155.
  33. Almutairi S., Kalloush H.M., Manoon N.A., Bardaweel S.K. Matrix Metalloproteinases Inhibitors in Cancer Treatment: An Updated Review (2013-2023) // Molecules, 2023; 28: 5567.
  34. Winer A., Adams S., Mignatti P. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes // Mol Cancer Ther., 2018;17(6):1147-1155.